Towards Automated Manufacturing for Cell Therapies

• Published in: Current hematologic malignancy reports 2019-08, Vol.14 (4), p.278-285
• Main Authors: Smith, David, Heathman, Thomas R. J., Klarer, Alex, LeBlon, Courtney, Tada, Yasuhiko, Hampson, Brian
• Format: Article
• Language: English
• Subjects: CART and Immunotherapy (M Ruella and P Hanley; Geriatrics/Gerontology; Hematology; Medicine; Medicine & Public Health; Oncology; Section Editors; Topical Collection on CART and Immunotherapy
• ISSN: 1558-8211; 1558-822X
• DOI: 10.1007/s11899-019-00522-y

Purpose of Review Many cell therapy products are beginning to reach the commercial finish line and a rapidly escalating pipeline of products are in clinical development. The need to develop manufacturing capability that will support a successful commercial business model has become a top priority as many cell therapy developers look to secure long-term visions to enable both funding and treatment success. Recent Findings Manufacturing automation is both highly compelling and very challenging at the same time as a key tactic to address quality, cost of goods, scale, and sustainability that are fundamental drivers for commercially viable manufacturing. Summary This paper presents an overview and strategic drivers for application of automation to cell therapy manufacturing. It also explores unique automation considerations for patient-specific cell therapy (PSCT) where each full-scale lot is for one patient vs off-the-shelf cell therapy (OTSCT) where a full-scale lot will treat many patients, and finally some practical considerations for implementing automation.